Faciocervical Group B Streptococcal Necrotising Fasciitis: a Multidisciplinary Approach Management

BMJ Case Rep. 2023 Dec 7;16(12):e255874. doi: 10.1136/bcr-2023-255874.

Abstract

Neonatal necrotising fasciitis secondary to Streptococcus agalactiae, also known as Group B Streptococcus (GBS), is a rare, life-threatening entity with approximately 40 cases reported in the literature.1 GBS soft tissue infection in infancy most commonly affects the face, likely originating from the colonised oral cavity.2 In cases unresponsive to medical management alone, early surgical debridement can be life-saving. We present a case of faciocervical GBS necrotising fasciitis in a male neonate requiring multiple surgical debridements. The resultant soft tissue defect healed with topical negative pressure therapy and eventual placement of a double-layer dermal substitute. Due to his prematurity, the patient was not skin grafted to limit donor site morbidity. After recovering from his life-threatening infection, the patient had intensive scar therapy leading to a favourable cosmetic result with no evidence of function-limiting contracture. Our report draws focus to the need for a multidisciplinary approach incorporating therapy-led scar management early in the postsurgical recovery plan.

Keywords: Paediatric Surgery; Paediatrics; Physiotherapy (rehabilitation); Plastic and reconstructive surgery; Public health.

Publication types

  • Case Reports

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Cicatrix / complications
  • Debridement
  • Fasciitis, Necrotizing* / surgery
  • Humans
  • Infant, Newborn
  • Male
  • Negative-Pressure Wound Therapy*
  • Streptococcal Infections* / complications
  • Streptococcus agalactiae
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents